<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
<channel>
<title>Annals of Clinical Endocrinology and Metabolism</title>
<link>https://www.theskygallerypattaya.com/hcem</link>
<description>A Heighpubs Open Access Journal</description>
<language>en-us</language>
	<item>
		<title>COVID-19 associated hyperthyroidism due to destructive thyrotoxicosis in a young female patient</title>
		<pubDate>07/27/2020</pubDate>
		<link>https://www.theskygallerypattaya.com/hcem/acem-aid1016.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;SARS-CoV2 can induce multiple immunological and endocrinological changes. We report the case of a COVID-19 associated hyperthyroidism in a young female.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;Per definition the patient &amp;amp;ndash; because of having given birth six weeks previously - had a postpartum thyroiditis. However thus no antibodies were detected, the thyroiditis ceased without medication after the dissolving of the virus disease and the fT3/fT3-ratio proved a destructive thyreopathy as well as there was a close time link onset of the symptoms with the novel corona virus infection we argue it to be a COVID-19 induced thyrotoxicosis.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;This proves the ability of SARS-CoV-2 to alter thyroid function, therefore all COVID-19 patients should be monitored regarding endocrinological changes and TSH, fT3, fT4 should be assessed.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Management of gestational diabetes during â€˜COVID19 timeâ€™</title>
		<pubDate>05/27/2020</pubDate>
		<link>https://www.theskygallerypattaya.com/hcem/acem-aid1015.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;The measures put in place by many governments around the world to fight the spread of COVID-19 have drastically reduced visits to diabetes centres. To keep providing people with diabetes the professional support they need and reduce the inconvenience caused by the interruption of traditional assistance, the typical control visit can be carried out by virtual visit, telemedicine (TM) that should have the necessary characteristics to provide a correct execution. Especially this is important for pregnant women first diagnosed with gestational diabetes mellitus (GDM), they have the necessity to frequent checks in a short time due to the pregnancy.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Risk Factors Associated to Patients with Type 2 Diabetes in Lahore District</title>
		<pubDate>05/21/2020</pubDate>
		<link>https://www.theskygallerypattaya.com/hcem/acem-aid1014.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Our research aimed to check the impact of some significant risk variables on diabetes growth and the specific goal of this study was to evaluate the connection of industrial fields with diabetes risk variables. The current research also informs us about the most important risk factor for male and female people with diabetes. A cross-section and convenient sample of 100 people, male and female, without discernment of risk factors and diabetes mellitus (Meta-Analysis on the effect of major risk factors on the diabetic patients form Jinnah Hospital Lahore). The risk factors in the general assessment i.e. lack of exercise, kidney problems, high ranges of tests and residence in industrial areas are found to be significant. Assessment of these factors is helpful in early diagnosis and in prognosis of diabetes.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Diagnostic imaging in congenital adrenal hyperplasia â€“ how does it help?</title>
		<pubDate>04/29/2020</pubDate>
		<link>https://www.theskygallerypattaya.com/hcem/acem-aid1013.php</link>
		<description>&amp;lt;h2&amp;gt;Summary&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;The phenotypic manifestation of congenital adrenal hyperplasia (CAH) is variable, and this largely depends on the extent of 21-Hydroxylase enzyme deficiency. In non- classic CAH (NCCAH), the clinical features predominantly reflect the androgen excess rather than adrenal insufficiency. In boys, the condition may not present until much later in childhood, where the diagnosis is made following presentation with precocious puberty, features of aldosterone insufficiency, or this condition may be detected during fertility workup.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;Imaging is generally not used in the evaluation of CAH, but may be helpful for the diagnosis, management, and follow-up of these patients. CAH can result in adrenal enlargement in both classic and non-classic forms of adrenal hyperplasia. The so-called adrenal rest tissue may be seen at several sites throughout the body, including the celiac plexus region, broad ligaments, normal ovaries, and testes. Sustained elevation of adrenocorticotropic hormone (ACTH) in patients with CAH has been postulated to cause adrenal rest cells to grow and become functionally active. The discovery of bilateral adrenal enlargement during radiologic evaluation for unrelated disease processes might serve as a mode of presentation for clinically not apparent or non- classical congenital adrenal hyperplasia (NCCAH).&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Type 2 diabetes and cancer</title>
		<pubDate>02/28/2020</pubDate>
		<link>https://www.theskygallerypattaya.com/hcem/acem-aid1012.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Diabetes mellitus increases the possibility of different cancers. Scientists have substantiated the link of diabetes with increased prevalence, augmented progression and improved cancer aggression. Research has strengthened link of diabetes with the colorectal cancer risk among various cancers. Diagnosis and treatment have made some progress in recent years, but Colorectal is major issue for the health of people even today. In order to reduce cancer mortality, there is importance of prophylaxis, evaluation and proper treatment. Factors distressing cancer prognosis is required by policy-making system for beneficial approaches of cancer patients and improvement of disease. Eventually diabetes- specific strategies for different cancers are explored.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Could metabolic risk factors contribute to the development of cervical cancer?</title>
		<pubDate>12/18/2019</pubDate>
		<link>https://www.theskygallerypattaya.com/hcem/acem-aid1011.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;The role of human papillomavirus infection as etiological factor for cervical squamous intraepithelial lesions and cervical cancer is well established. However, the presence of this virus is not sufficient condition for developing of cervical cancer. Currently, the contribution of other viral, environmental and host cofactors in triggering of this neoplasm is being investigated. Some metabolic risk factors have been associated with the development of several gynecological cancers such as endometrium, ovary and cervix. However, the mechanisms through which these factors contribute to carcinogenesis are complex and not fully elucidated. Few interventions regarding host metabolic factors have been performed on women at risk of developing cervical cancer. Some specific treatments and or changes in lifestyles could be carried out to avoid or delay progression to this kind of cancer. This paper aims to enlarge and update this topic based on the article &amp;amp;uml;Association between components of the metabolic syndrome and degree of cervical squamous intraepithelial lesions in Cuban women&amp;amp;uml;, with emphasis on possible mechanisms that explain the link between central adiposity, insulin resistance and dyslipidemia with risk of premalignant lesions and cervical cancer.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Endocrine abnormalities in two siblings with Rothmund Thomson Syndrome</title>
		<pubDate>10/11/2018</pubDate>
		<link>https://www.theskygallerypattaya.com/hcem/acem-aid1010.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Rothmund-Thomson syndrome is a rare autosomal recessive disorder characterized by poikiloderma (skin atrophy, telangiectasia, hyper- and hypopigmentation), congenital skeletal abnormalities, short stature, premature aging, and increased risk of malignant disease. Two siblings with Rothmund-Thomson Syndrome showed the following characteristic features: severe growth failure, dystrophic nails, absent eyelashes/eyebrows, small hands, clinodactyly, microdontia and congential poikiloderma. In addition, delayed sexual development with cryptorchidism in the male and Hashimato thyroiditis in the female patient were detected. These cases are presented here because of these endocrine patterns, with the aim of drawing attention to the invisible aspects of Rothmund-Thomson syndrome.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Comparison of Efficacy and Safety of Hydroxychloroquine and Teneligliptin in Type 2 Diabetes Patients who are Inadequately Controlled with Glimepiride, Metformin and Insulin therapy: A Randomized Controlled Trial with Parallel Group Design</title>
		<pubDate>09/13/2018</pubDate>
		<link>https://www.theskygallerypattaya.com/hcem/acem-aid1009.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Aim:&amp;lt;/strong&amp;gt; The aim of the present study is to assess the efficacy and safety of Hydroxychloroquine in comparison with Teneligliptin in type 2 diabetes patients whose blood glucose levels were inadequately controlled with metformin, Glimepiride and insulin therapy.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Methods:&amp;lt;/strong&amp;gt; This was a randomized, prospective, parallel-group, experimental trial done in 300 Type 2 Diabetes patients who were uncontrolled (HbA1c=7.5&amp;amp;ndash;10%) with metformin, Glimepiride and insulin therapy. Patients were randomly divided into two groups one received Teneligliptin 20 mg (n=152) and other received Hydroxychloroquine 400 mg (n=148) while continuing insulin therapy with other 2 OHA. Insulin doses were adjusted to maintain normal blood glucose levels.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Result: &amp;lt;/strong&amp;gt;The adjusted mean change from baseline to endpoint in HbA1c was &amp;amp;minus;1.2&amp;amp;plusmn;0.5% in patient group receiving Hydroxychloroquine and &amp;amp;minus;0.9&amp;amp;plusmn;0.5% in patients group receiving Teneligliptin, respectively, with a significant between-treatment difference (p&amp;amp;lt;0.001). The incidence of adverse events was similar in the Hydroxychloroquine (72%) and Teneligliptin (77%) groups. However, hypoglycaemic events were less common (p&amp;amp;lt;0.001) and less severe (p&amp;amp;lt;0.05) in patients receiving Hydroxychloroquine than in those receiving Teneligliptin.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Conclusion: &amp;lt;/strong&amp;gt;Hydroxychloroquine decreases HbA1c in patients whose type 2 diabetes is poorly controlled with high doses of insulin as compare to Teneligliptin. Addition of hydroxychloroquine to insulin therapy is also associated with reduced incidence of confirmed and severe hypoglycaemia.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>A Pancreatic Neuroendocrine Tumor with an Unusual Flush</title>
		<pubDate>08/14/2018</pubDate>
		<link>https://www.theskygallerypattaya.com/hcem/acem-aid1008.php</link>
		<description>&amp;lt;h2&amp;gt;Summary&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;A 60-year-old man presented with an unusual history of lower limb flushing. A CT scan suggested a pancreatic neuroendocrine tumor. After a robotic distal pancreatectomy, his symptoms completely resolved. The tumor was positive for synaptophysin and chromogranin. This case emphasizes the importance of recognizing atypical features in patients, especially with an unusual skin presentation that might indicate rare tumor types.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Exercise preserves pancreatic Î²-cell mass and function in obese OLETF rats</title>
		<pubDate>06/19/2018</pubDate>
		<link>https://www.theskygallerypattaya.com/hcem/acem-aid1007.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Although exercise has been proposed to be beneficial to type 2 diabetes, its effects on &amp;amp;beta;-cell function and mass remain unclear. In the present study, the effects of long-term swimming training on the function and mass of &amp;amp;beta;-cells in diabetic OLETF rats were examined. At 44 weeks of age after developing diabetes, the OLETF rats were divided into two groups: a control group and an exercise group. The exercise group had a daily swimming for 12 weeks. While not found with the control rats, in the obese OLETF rats, the exercise reduced the weight gain which was associated with improved glucose tolerance and elevated circulating insulin levels as determined by the oral glucose tolerance test and insulin ELISA. The exercise improved plasma total cholesterol and triglyceride levels, and also significantly increased the islet &amp;amp;beta;-cell mass and pancreatic insulin content associated with decreased &amp;amp;beta;-cell apoptosis and elevated activation of the serine/threonine kinase, Akt. The present studies suggest that exercise improves diabetes symptoms via enhancement of the &amp;amp;beta;-cell mass and function through decreasing glucolipotoxicity and reducing &amp;amp;beta;-cell apoptosis by activating Akt in obese OLETF rats.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>New pharmacological strategies in some metabolic endocrine disorder under a toxicological approach</title>
		<pubDate>03/09/2018</pubDate>
		<link>https://www.theskygallerypattaya.com/hcem/acem-aid1006.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;In this review After Observing biomedical literature (starting from some heart disease) results that some pathological phenomena are deeply involved in some metabolic endocrine condition: Kinetics and gradients in metabolism, catabolism, time related, toxic like effect, electrical cell membrane status, smooth vascular muscle cell hyper-reactivity, platelet iperactivations, central autonomic control after acute stroke, great electrolytes unbalances et other factors as pro-hypertrophic signaling and oxidative stress. Observing actual current therapy in some metabolic endocrine therapy often is used association of drugs (in example in type II diabetes). In Many other pathologies efficacy drug therapy exist, and often only 1 pharmacological molecule resolve the pathological condition. But in many disease even associating 2-3-4 drugs the % of cure not increase (efficacy, effectiveness). It mean that this drugs strategies are not the really best? Or it mean a low active level? Why for this pathological condition this association drugs in currently use not do the right works as really needed? There is the need for new really efficacy drugs strategy that show a profile of efficacy as requested in order to resolve the pathological condition? Or to be added to the actual therapy? The actual pharmacological strategies in some metabolic endocrine disorder is really the best? Or other strategies can be introduced?&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Indian spices and Caffeine treatment for Obesity and Cardiovascular disease</title>
		<pubDate>01/31/2018</pubDate>
		<link>https://www.theskygallerypattaya.com/hcem/acem-aid1005.php</link>
		<description>&amp;lt;h2&amp;gt;Editorial&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;The global obesity epidemic that was previously reported [1,2] is now to worsen with obesity to double in 73 countries around the world [3,4]. Improving the health of obese individuals by dietary restriction, anti-obese foods and increased physical activity [1] has not reduced the global obesity epidemic. Obesity is linked to nonalcoholic fatty liver disease (NAFLD) [5,6] with complications relevant to the metabolic syndrome and cardiovascular disease [7]. Appetite control has become critical to endocrinology and metabolism with the apelinergic pathway and nuclear receptor Sirtuin 1 (Sirt 1) now connected to the endocrine system [8] and critical to metabolism. The apelin-Sirt 1 interaction involves nitric oxide (NO) [9] that is now considered as the defect [10] in the interaction between the peptide apelin and calorie sensitive gene Sirt 1 involved in NO imbalances in the adipose tissue, liver and the brain.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Diabetes and red blood parameters</title>
		<pubDate>01/08/2018</pubDate>
		<link>https://www.theskygallerypattaya.com/hcem/acem-aid1004.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;Type 2 diabetes is a common disease in these days and day by day it is arising. The main focus of the study was to investigate association of packed cell volume (PCV), Mean Corpuscular Volume (MPV), Mean Corpuscular Hemoglobin Concentration (MCHC), Red Cell Distribution Width (RDW) with glycemic marker HbA1c. So that PCV, MPV, MCHC, RDW could be used as a predictor of glucoregulation in type 2 diabetes instead of HbA1c value. This study included 87 DMT2 patients, which divided into two groups, A (n=41, presence in diabetics&amp;amp;le;6.5-6.9%) and B (n=46, target in diabetes&amp;amp;ge;7.0%), according to HbA1c values. Spearsman correlation co-efficients were calculated to evaluate the relationship between RBC count, MCHC, RDW with random blood sugar (RBS) and PCV, MCV, MCHC with HbA1c value. Binominal logistic regression analysis was performed to estimate the relationship between glycemic control, as dichotomous outcome of MCHC, RDW, PCV, and MCV as the main prognosticator. MCHC and RDW were significantly higher in the group B compared to the group A. RDW and MCHC may be applied as the auxiliary indicators of deterioration of glucoregulation.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Parathyroid Functions in Thalassemia Major Patients</title>
		<pubDate>08/29/2017</pubDate>
		<link>https://www.theskygallerypattaya.com/hcem/acem-aid1003.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Background:&amp;lt;/strong&amp;gt; Hypoparathyroidism is well known to occur in thalassemia major patients, but it is thought to be uncommon and its incidence is considered to be decreasing with improvements in chelation therapy. The objective of this study was to assess the prevalence of parathyroid dysfunction in the first decade of life of the patients with thalassemia major.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Patients and Methods:&amp;lt;/strong&amp;gt; Ninety children with beta-thalassemia major (55 males and 35 females) with a mean age of 7.17&amp;amp;plusmn;3.78 years (1-13 years) and age and sex matched control group of 60 healthy children (36 males and 24 females) with a mean age 6.98&amp;amp;plusmn;3.66 years (1-13) years. Serum parathyroid hormone (PTH), serum total Calcium (Ca), serum phosphorus (P), serum alkaline phosphatase (ALP), serum 25-hydroxyvitamin D (25-OHD) and serum ferritin levels were measured.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Result:&amp;lt;/strong&amp;gt; PTH levels were higher than normal range in 23 (25.6%) patients with a mean value of 75.2&amp;amp;plusmn;31.3 &amp;amp;micro;g/mL compared to those having normal range level (35.3&amp;amp;plusmn;15.2 &amp;amp;micro;g/mL). Ca levels were found low in 11 patients (12.2%), and P levels were found high in 2 (2.22%) and low in 4 (4.44%) patients while high ALP levels were found in 6 (6.67%) patients. 25-OHD levels were low in all patients with a mean value of 24.95&amp;amp;plusmn;5.82.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Conclusion:&amp;lt;/strong&amp;gt; Reports in the literature indicate that parathyroid dysfunction due to iron overload generally occurs in 2nd or 3rd decade of patients with thalassemia major. However, our study shows that PTH due to iron overload may develop in a significant number of thalassemia major patients, therefore, all thalassemics should be carefully watched for endocrine organ function such as hyperparathyroidism might occur even in the first decade of the patients with thalassemia major.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Effect on Vitamin D status of Breastfeeding Infants after Vitamin D3 Supplementation during Breastfeeding Lactation: A double-blind randomized controlled trial</title>
		<pubDate>08/04/2017</pubDate>
		<link>https://www.theskygallerypattaya.com/hcem/acem-aid1002.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Background:&amp;lt;/strong&amp;gt; Vitamin D deficiency in pregnancy increases several risks of breastfed mothers. To prevent these adverse events, vitamin D supplementation during pregnancy and lactation is recommended, but suggested dose ranges vary.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Objective:&amp;lt;/strong&amp;gt; To determine whether vitamin D3 1,800 IU/d supplementation in lactating mothers improves the vitamin D status of their breastfed infants.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Materials and Methods:&amp;lt;/strong&amp;gt; A randomized, placebo&amp;amp;ndash;controlled trial with Thai pregnant women was conducted. Lactating mothers (n=72) and their breastfed infants with insufficient maternal 25 hydroxyvitamin D (25(OH)D) levels in the third trimester were randomly assigned to two groups, one of which received 1,800 IU/d vitamin D supplementation and the other a placebo. Maternal serum 25(OH)D during lactation, cord blood, and 6-week breastfed infant serum were measured using LC-MS/MS.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Results: &amp;lt;/strong&amp;gt;Mean maternal age (&amp;amp;plusmn;SD) was 27&amp;amp;plusmn;5 years, and pre-gestational BMI was 22.29&amp;amp;plusmn;5 kg/m2. Maternal serum 25(OH)D at baseline was 22.29&amp;amp;plusmn;7.15 nmol/L. At 6 weeks, both maternal 25(OH)D and infant 25 (OH)D levels had increased significantly in the vitamin D supplement group of mothers and infants (68.30&amp;amp;plusmn;15.40, 40.40&amp;amp;plusmn;12.56 nmol/L) compared to those in placebo groups (55.15&amp;amp;plusmn;13.57, 24.28&amp;amp;plusmn;17.20 nmol/L) (p &amp;amp;lt;0.001, p&amp;amp;lt;0.001). The changes in infant 25(OH)D levels increased substantially in the vitamin D supplement group but decreased in placebo(17.49&amp;amp;plusmn;16.27 ng/ml compared to -1.34&amp;amp;plusmn;19.23 nmol/L in the placebo group, p&amp;amp;lt;0.001). The change of maternal 25(OH)D were positively correlation to the change of 25(OH)D level in breastmilk mothers and infants by r=0.697, p&amp;amp;lt;0.001 and r=0.379, p=0.003 respectively.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Conclusions: &amp;lt;/strong&amp;gt;Vitamin D3 supplementation to breastfed mother during lactation can increase serum 25(OH)D level in Thai breastfed mother and infants. Further work is needed to determine the optimum duration of vitamin D supplementation to normalized breastfed infants with 25(OH)D level &amp;amp;gt;75 nmol/L.&amp;lt;/p&amp;gt;</description>
	</item>
	<item>
		<title>Recurrent Cardiac Events Driven by Prothrombotic Burden in a Patient Undergoing Lipoprotein Apheresis for High Lp(a) Levels</title>
		<pubDate>03/15/2017</pubDate>
		<link>https://www.theskygallerypattaya.com/hcem/acem-aid1001.php</link>
		<description>&amp;lt;h2&amp;gt;Abstract&amp;lt;/h2&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Introduction:&amp;lt;/strong&amp;gt; Lipoprotein (a) [Lp(a)] is a marker for cardiovascular disease, involved in pathogenesis and progression of atherosclerosis. In selected high-risk patients, lipoprotein-apheresis could optimize secondary prevention and improve prognosis.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Aim:&amp;lt;/strong&amp;gt; We presented the case of a 49-year-old man with high lipoprotein (a) levels and recurrent cardiac adverse events, despite maximal pharmacological therapy.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Case report:&amp;lt;/strong&amp;gt; Four years before the admission at our Centre, he presented an anterior STEMI, treated with angioplasty and implantation of a drug eluting stent on left anterior descending artery, at the age of 47 years, in September 2012; one month later, the patients presented a new episode of angina, and exams showed a critical stenosis in the right coronary artery, treated by angioplasty and implantation of drug eluting stent. Because of high Lp(a) plasma levels, patient was subsequently on regularly 7-10 day lipoprotein apheresis.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Results and discussion:&amp;lt;/strong&amp;gt; A thrombophilic screening was performed, showing the simultaneous presence of heterozygous V Leiden mutation and prothrombin G20210A mutation. He referred to our Centre in order to optimize therapy; we performed an endothelial function assessment showing a severe dysfunctional pattern.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;Because of these findings, we prescribed dual antiplatelet therapy, and we added omega-3 fatty acids and association with nicotinic acid/laropiprant. According with current guidelines, considering the high risk of bleeding, we preferred not to administer anticoagulant therapy. At 6-month and 1-year follow up the patient continued lipoprotein apheresis and was asymptomatic for other cardiovascular events.&amp;lt;/p&amp;gt;

&amp;lt;p&amp;gt;&amp;lt;strong&amp;gt;Conclusions:&amp;lt;/strong&amp;gt; The assessment for the eventual presence of thrombophilia might become a useful tool in clinical practice for high-risk selected patients.&amp;lt;/p&amp;gt;</description>
	</item>
</channel>
</rss>